Home › Epigenomics' Q1 Revenues Drop 5 Percent

Epigenomics' Q1 Revenues Drop 5 Percent

May 10, 2017

NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
12
Featured Webinar

Precision Metagenomics to Identify Patients at Risk for Invasive Infection

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

What's Popular?

In Molecular Diagnostics

  1. Qiagen to Develop Companion Dx for Novartis Breast Cancer Drug

  2. Grail Launches New Early Cancer Detection Study, Refocuses Strategy to Multi-Cancer Test

    Premium

  3. Cancer Whole-Genome and Transcriptome Test Expands NYGC's Clinical Services

    Premium

  4. SpeeDx Gets CE-IVD Mark for Antibiotic-Resistant Gonorrhea MDx

  5. Study Adds to Evidence for Genelex PGx Testing But Proving Value Remains Difficult, Authors Say

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.